Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety Trial of rAAV2/8-hCYP4V2 Gene Replacement Therapy Drug Administered as a Single Subretinal Injection in Patients With Bietti's Crystalline Dystrophy (BCD)

NCT04722107 is registered in ClinicalTrials.gov with Beijing Tongren Hospital as lead sponsor.

NCT NCT04722107
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04722107 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety Trial of rAAV2/8-hCYP4V2 Gene Replacement Therapy Drug Administered as a Single Subretinal Injection in Patients With Bietti's Crystalline Dystrophy (BCD)
Lead sponsor
Beijing Tongren Hospital
Phase
Phase 1
Overall status
Unknown status
Start date
April 21, 2021
Completion date
April 29, 2024
Enrollment
12 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

bietti's crystalline dystrophy